Microglial crosstalk with astrocytes and immune cells in amyotrophic lateral sclerosis

Front Immunol. 2023 Jul 26:14:1223096. doi: 10.3389/fimmu.2023.1223096. eCollection 2023.

Abstract

In recent years, biomedical research efforts aimed to unravel the mechanisms involved in motor neuron death that occurs in amyotrophic lateral sclerosis (ALS). While the main causes of disease progression were first sought in the motor neurons, more recent studies highlight the gliocentric theory demonstrating the pivotal role of microglia and astrocyte, but also of infiltrating immune cells, in the pathological processes that take place in the central nervous system microenvironment. From this point of view, microglia-astrocytes-lymphocytes crosstalk is fundamental to shape the microenvironment toward a pro-inflammatory one, enhancing neuronal damage. In this review, we dissect the current state-of-the-art knowledge of the microglial dialogue with other cell populations as one of the principal hallmarks of ALS progression. Particularly, we deeply investigate the microglia crosstalk with astrocytes and immune cells reporting in vitro and in vivo studies related to ALS mouse models and human patients. At last, we highlight the current experimental therapeutic approaches that aim to modulate microglial phenotype to revert the microenvironment, thus counteracting ALS progression.

Keywords: Astrocyctes; amytrophic lateral sclerosis (ALS); immune cell; inflammation; microglia.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis* / genetics
  • Animals
  • Astrocytes / pathology
  • Humans
  • Mice
  • Microglia / pathology
  • Motor Neurons / pathology

Grants and funding

SG was supported by A0112E0073 Funding Source: Regione Lazio POR FSE 2014-2020 PRATT25118; NextGenerationEU” DD. 3175/2021 E DD. 3138/2021 CN_3: National Center for Gene Therapy and Drugs based on RNA Technology Codice Progetto CN 00000041; RF GR-2021-12372494. G.C. was supported by NextGenerationEU” DD. 3175/2021 E DD. 3138/2021 CN_3: National Center for Gene Therapy and Drugs based on RNA Technology Codice Progetto CN 00000041. C.L. was supported by RF-2018-12366215; Next Generation EU PNRR Rome Technopole Flagship 7; Ateneo Sapienza “SEED” PNR 2022.